UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®â–¼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback